Dr. John Cush RheumNow
3 years 9 months ago
#ACR22 - Day 2 Part III
RheumNow and its reporters review abstracts presented on Day 2 of #ACR22.
https://t.co/uUiX7s5Ajf https://t.co/0E5KSpOyyL
Dr. John Cush RheumNow
3 years 9 months ago
Survival and Mortality in RA: time to move away from “one-size fits all”?
Dr. Aurelie Najm ( @AurelieRheumo ) reviews Abstract #0246 at #ACR22.
https://t.co/O4dNzCZmmd https://t.co/cWUXEpduID
Dr. John Cush RheumNow
3 years 9 months ago
Exciting Data for SLE: Plenaries from #ACR22
Dr. Michael Putman ( @EBRheum ) shares SLE updates shared at #ACR22.
https://t.co/34HAvc2S8F https://t.co/xINo52fF2O
Dr. John Cush RheumNow
3 years 9 months ago
Can computers tell the difference between RA & PsA?
Dr. David Liew ( @drdavidliew) discusses Abstract 0242 presented at #ACR22. Abstract 0242: Neural Networks for Distinguishing RA from PsA by Using Magnetic Resonance Imaging
https://t.co/ZL5TYIdT6Q https://t.co/tZWIAl0rb0
Dr. John Cush RheumNow
3 years 9 months ago
Upadacitinib vs Adalimumab in PsA using RAPID3
Dr. Catherine Sims ( @DrCassySims) discusses abstract 0192 presented at #ACR22. 0192: Upadacitinib versus Adalimumab on Routine Assessment of Patient Index Data 3 (RAPID3) in Patients with PsA,
https://t.co/nRjgM45GdO https://t.co/MDqpW7ACXa
Dr. John Cush RheumNow
3 years 9 months ago
#ACR22 Rheumatology Roundup w/ Drs. Kavanaugh & Cush
#1044 Combo Rx SpA
#0533 CCP spit
#1604 StopRA
#2251 Tofa & RA ILD
#0420 NSAID SpA
#002 CA in IIM
#0113 BTK Sjogrens
#L05 Prolia EOA
#0526 Pexivas
#1106 TCZ PMR
Video: https://t.co/JG3spEsYDD
Podcast: https://t.co/nbmeiGo2yt https://t.co/E7RDPTFsaS
Dr. John Cush RheumNow
3 years 9 months ago
Urinary Biomarkers in Lupus
Dr.Cush interviews Dr. Fava about Abstract 536 at #ACR22. Abstract 0536: Change in Urinary Biomarkers at Three Months Predicts 1-year Treatment Response of Lupus Nephritis Better Than Proteinuria
https://t.co/3IfPdTMufb https://t.co/XVECG9mJri
The ACR Great Debate was on "To treat or not to treat in pre-RA?". What is the clinician to do?
Despite the fact that polymyalgia rheumatica is the most prevalent inflammatory rheumatic disease in those over 65 years of age, progress in its diagnosis, monitoring and management have failed to garner momentum in decades past.
However, ACR22 has fostered significant promise for its future.
It was great to be back at an ACR annual meeting, this one in Philadelphia - Philly was great. A walking town, rich in culture, history and good places to meet and mingle.
I loved the city, but not the convention center (not easy to navigate).
Dr. John Cush RheumNow
3 years 9 months ago
Social Media in Academic Rheumatology
Dr. Kathryn Dao and Jorena Lim discuss the impact of social media in rheumatology. @KDAO2011
https://t.co/a6yoH745Ap https://t.co/RioB7n9fWZ
Dr. John Cush RheumNow
3 years 9 months ago
Dual target blockade may be better than one in SLE
Dr. Yusof ( @Yuz6Yusof) discusses abstracts #L07 and #1001 presented at #ACR22.
https://t.co/20MGDHBLT1 https://t.co/4IcBKn1IKg
